Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study

Napapon Sailasuta, Kent Harris, Thao Tran, Brian RossClinical MR Unit, Huntington Medical Research Institutes, Pasadena, CA, USAAbstract: We applied 13C magnetic resonance spectroscopy (MRS), a nonradioactive, noninvasive brain imaging technique, to quantify the oxidation of [1-13C] acetate in a con...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tran T, Harris K, Sailasuta N, Ross B
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://doaj.org/article/5ba6dcdf4ac942c3afd7e47b352ab4ae
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5ba6dcdf4ac942c3afd7e47b352ab4ae
record_format dspace
spelling oai:doaj.org-article:5ba6dcdf4ac942c3afd7e47b352ab4ae2021-12-02T03:27:57ZMinimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study1176-63281178-2021https://doaj.org/article/5ba6dcdf4ac942c3afd7e47b352ab4ae2011-08-01T00:00:00Zhttp://www.dovepress.com/minimally-invasive-biomarker-confirms-glial-activation-present-in-alzh-a8143https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Napapon Sailasuta, Kent Harris, Thao Tran, Brian RossClinical MR Unit, Huntington Medical Research Institutes, Pasadena, CA, USAAbstract: We applied 13C magnetic resonance spectroscopy (MRS), a nonradioactive, noninvasive brain imaging technique, to quantify the oxidation of [1-13C] acetate in a conventional clinical magnetic resonance imaging (MRI) scanner in five consecutive elderly subjects at various clinical stages of Alzheimer's disease (AD) progression. [1-13C] acetate entered the brain and was metabolized to [5-13C] glutamate and glutamine, as well as [1-13C] glutamate and glutamine, and the final glial oxidation product, 13C bicarbonate, at a linear rate. Calculation of the initial slope was similar in a single subject, examined twice, 1 month apart (test-re-test 8%). Mean rate of cerebral bicarbonate production in this elderly group was 0.040 ± 0.01 (n = 5). Assuming that the rate of conversion of acetate to bicarbonate is a reflection of glial metabolic rate and that glial metabolic rate is a surrogate marker for 'neuroinflammation', our preliminary results suggest that [1-13C] MRS may provide biomarkers for diseases, believed to involve microglia and other cells of the astrocyte series. Among these is AD, for which novel drugs which ameliorate the damaging effects of neuroinflammation before symptoms of dementia appear, are in advanced development. The value of 13C MRS as an early, noninvasive biomarker may lie in the conduct of cost-effective clinical trials.Keywords: Alzheimer's disease, noninvasive biomarker, glial activationTran THarris KSailasuta NRoss BDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 495-499 (2011)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Tran T
Harris K
Sailasuta N
Ross B
Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study
description Napapon Sailasuta, Kent Harris, Thao Tran, Brian RossClinical MR Unit, Huntington Medical Research Institutes, Pasadena, CA, USAAbstract: We applied 13C magnetic resonance spectroscopy (MRS), a nonradioactive, noninvasive brain imaging technique, to quantify the oxidation of [1-13C] acetate in a conventional clinical magnetic resonance imaging (MRI) scanner in five consecutive elderly subjects at various clinical stages of Alzheimer's disease (AD) progression. [1-13C] acetate entered the brain and was metabolized to [5-13C] glutamate and glutamine, as well as [1-13C] glutamate and glutamine, and the final glial oxidation product, 13C bicarbonate, at a linear rate. Calculation of the initial slope was similar in a single subject, examined twice, 1 month apart (test-re-test 8%). Mean rate of cerebral bicarbonate production in this elderly group was 0.040 ± 0.01 (n = 5). Assuming that the rate of conversion of acetate to bicarbonate is a reflection of glial metabolic rate and that glial metabolic rate is a surrogate marker for 'neuroinflammation', our preliminary results suggest that [1-13C] MRS may provide biomarkers for diseases, believed to involve microglia and other cells of the astrocyte series. Among these is AD, for which novel drugs which ameliorate the damaging effects of neuroinflammation before symptoms of dementia appear, are in advanced development. The value of 13C MRS as an early, noninvasive biomarker may lie in the conduct of cost-effective clinical trials.Keywords: Alzheimer's disease, noninvasive biomarker, glial activation
format article
author Tran T
Harris K
Sailasuta N
Ross B
author_facet Tran T
Harris K
Sailasuta N
Ross B
author_sort Tran T
title Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study
title_short Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study
title_full Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study
title_fullStr Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study
title_full_unstemmed Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study
title_sort minimally invasive biomarker confirms glial activation present in alzheimer's disease: a preliminary study
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/5ba6dcdf4ac942c3afd7e47b352ab4ae
work_keys_str_mv AT trant minimallyinvasivebiomarkerconfirmsglialactivationpresentinalzheimeramp39sdiseaseapreliminarystudy
AT harrisk minimallyinvasivebiomarkerconfirmsglialactivationpresentinalzheimeramp39sdiseaseapreliminarystudy
AT sailasutan minimallyinvasivebiomarkerconfirmsglialactivationpresentinalzheimeramp39sdiseaseapreliminarystudy
AT rossb minimallyinvasivebiomarkerconfirmsglialactivationpresentinalzheimeramp39sdiseaseapreliminarystudy
_version_ 1718401730438234112